Source: MarketScreener

Terns Pharmaceuticals: Terns Pharmaceuticals to Present Data from an Ongoing Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH

(marketscreener.com) Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis and cancer, today announced it will present data at the Asian Pacific Association for the Study of the Liver , taking place in Bali, Indonesia, March 4-8, 2020. The company will give an...https://www.marketscreener.com/news/Terns-Pharmaceuticals-to-Present-Data-from-an-Ongoing-Phase-1-Clinical-Trial-of-TERN-201-a-SSAO-Inh--30118198/?utm_medium=RSS&utm_content=20200306

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Est. Annual Revenue
Est. Employees
Senthil Sundaram's photo - CEO of Terns

CEO

Senthil Sundaram

CEO Approval Rating

90/100

Terns is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of cancer and liver diseases. Read more